Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT3789 plus Keytruda in SMARCA4-mutant advanced solid tumors
2024-516889-11-00Phase 2Completed
- Sponsor
- Prelude Therapeutics
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of PRT3789 and pembrolizumab in non-small cell lung cancer (NSCLC), esophageal cancer and Nonhematologic neoplasms (2 arms), sponsored by Prelude Therapeutics. Primary endpoints: Incidence of dose-limiting toxicities, Adverse events and 2 more. Started Apr 2025; status: completed.
02
Drugs
PRT3789pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)esophageal cancerNonhematologic neoplasms
Beyond the preview
Go deeper on 2024-516889-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516889-11-00.